HOME >> BIOLOGY >> NEWS
Progenika Biopharma presents a biochip that guarantees safety in blood transfusions

The Basque biotechnology company, Progenika Biopharma, devoted to research and development in personalised medicine, have presented a DNA biochip, known as BLOODchip, which greatly eliminates the risk of adverse reactions due to incompatibility in blood groups between donor and receptor in blood transfusions.

With the aim of guaranteeing safety during blood transfusions, Progenika has developed and validated 1,000 clinical samples in cooperation with the principal European blood banks. Concretely, the validation of these samples was 99.8%, considerably higher than that produced using the current serology technique, which produces an error of 3%.

Thus, BLOODchip is currently the safest and most precise technique for genetically determining blood groups, enabling the reduction of adverse reactions in blood transfusions.

Two different techniques are currently used to detect possible incompatibilities in blood transfusions: the serological method and DNA sequencing. The serological technique has a limited capacity and does not allow the detection of 3% of the incompatibilities existing. DNA sequencing, while overcoming this drawback of the serological method, is however a slow and costly system.

Progenika has developed BLOODchip to respond to the disadvantages of the current systems. In this way, the totality of blood group incompatibilities are detected in a safer, quicker and more specific analytical process than with the serological technique. Moreover, its cost is twenty times less than DNA sequencing, which enables its generalized and routine use in all blood transfusions.

The BLOODchip is the result of research within the remit of the European Union IV Framework Programme and undertaken by Progenika in collaboration with the principal European blood banks.

It should be pointed out that Progenika Biopharma has developed and patented various products that are already on the market for several types of di
'"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
4-Jul-2007


Page: 1 2

Related biology news :

1. Science survey ranks top Biopharma employers
2. FDA grants Accentia Biopharmaceuticals...
3. Accentia Biopharmaceuticals announces option agreement with Mayo
4. AutovaxID-C introduced by Accentia Biopharmaceuticals
5. Accentia Biopharmaceuticals acquires exclusive license
6. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
7. SNM presents awards on Capitol Hill
8. ESA presents the sharpest ever satellite map of Earth
9. New book presents neurobiology from an evolutionary perspective
10. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
11. Childrens Hospital and Research Center-Oakland presents a new maternal diet study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... 2020 , ... Catalent, a global leader in clinical supply ... facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating in ... new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both ...
(Date:6/28/2020)... ... June 25, 2020 , ... Genedata, ... that it has entered into a multi-year contract with Merus N.V., a ... translational and clinical research strategy to discover and develop ground-breaking drugs. The ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm ... XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... ... is making available for free its new white paper – Simulated Transport ... testing into today’s biologics licensing application (BLA). In response, Modality Solutions shares ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and ... it did not take off as quickly as people initially expected, and where eSource ... capturing data electronically for clinical trials and then repurposing it for downstream analysis, at ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
Breaking Biology Technology:
Cached News: